SHAREHOLDER ALERT: Avid Bioservices Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
07 mars 2024 11h43 HE
|
Block & Leviton LLP
BOSTON, March 07, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Avid Bioservices, Inc. (NASDAQ: CDMO) for potential securities law violations. Investors who have lost money in their...
Avid Bioservices Announces Pricing of Private Placement of Convertible Notes
06 mars 2024 23h58 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today the pricing...
Avid Bioservices Announces Proposed Private Placement of Convertible Notes
06 mars 2024 16h32 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today that it...
Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024
06 mars 2024 16h31 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Rentschler Biopharma contributes to nearly 25% of FDA approved biopharmaceuticals in 2023
06 mars 2024 04h00 HE
|
Rentschler Biopharma SE
Exceptional capabilities in guiding therapies from early-stage development through to market based on over 50 years of biotech experience LAUPHEIM, Germany and MILFORD, Mass. and STEVENAGE, United...
Pharmaceutical Quality Management Systems Markets: Deviation, CAPA, Audit, Risk & Compliance, Inspection, Document, Change, Training Management - Global Forecast to 2030
01 mars 2024 04h46 HE
|
Research and Markets
Dublin, March 01, 2024 (GLOBE NEWSWIRE) -- The "Pharmaceutical Quality Management Systems Market by Solution Type (Deviation, CAPA, Audit, Risk & Compliance, Inspection, Document, Change,...
Lipid Nanoparticles (LNPs) CDMO Market Players are mainly Focusing on the Nucleic Acids LNPs - Here's Why | 2024 Exclusive InsightAce Report
01 mars 2024 01h43 HE
|
InsightAce Analytic Pvt. Ltd.
Jersey City, NJ, March 01, 2024 (GLOBE NEWSWIRE) -- “The Lipid Nanoparticles (LNPs) CDMO Market” in terms of revenue was estimated to be worth $182.0 Mn in 2023 and is poised to reach $518.2 Mn by...
Societal CDMO Enters Into Definitive Agreement to be Acquired by CoreRx, Inc.
28 févr. 2024 16h29 HE
|
Societal CDMO, Inc.
Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through Commercial Manufacturing and Packaging CoreRx to...
Berkshire Sterile Manufacturing Announces the Launch of Its Webinar Series, Perfecting Fill Finish
28 févr. 2024 13h00 HE
|
Berkshire Sterile Manufacturing
Lee, MA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Berkshire Sterile Manufacturing (BSM), a Massachusetts-based fill finish CDMO and subsidiary of Sharp, will launch a webinar series, Perfecting Fill...
Europe Nucleic Acid Therapeutics CDMO Market Analysis and Forecasts, 2023-2033: Increasing FDA or European Medicines Agency Approvals, Pharmaceutical Firms Becoming More Outsourcing-Oriented
28 févr. 2024 09h01 HE
|
Research and Markets
Dublin, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The "Europe Nucleic Acid Therapeutics CDMO Market: Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.The Europe...